IVD MEDICAL (01931) Confidentially Submits Draft F-1 Registration Statement for Proposed US Dual Listing

Stock News
09/30

IVD MEDICAL (01931) announced that the company has resolved to proceed with a proposed dual primary listing on the US NASDAQ Stock Market through a proposed initial public offering of American Depositary Shares representing new ordinary shares to be issued by the company. On September 29, 2025 (US Eastern Time), the company confidentially submitted a draft F-1 registration statement to the US Securities and Exchange Commission regarding the proposed offering.

This proposed US dual listing represents an important initiative in the group's global strategic expansion, and is expected to bring positive impacts across multiple dimensions:

• Expanding Global Financing Channels: Entry into one of the world's largest and most liquid capital markets is expected to attract more international long-term investors focused on biotechnology and healthcare sectors, providing strong capital support for the company's subsequent research and development and commercialization efforts.

• Enhancing International Brand Influence: Listing on NASDAQ will further elevate the company's corporate image and industry recognition in international markets, strengthening communication and collaboration opportunities with global potential partners, customers, and regulatory authorities.

• Improving Share Liquidity and Valuation Potential: By establishing cross-market trading mechanisms, this will help expand the investor base, enhance overall share liquidity, and fully reflect the company's long-term value in a more internationalized pricing environment.

• Optimizing Corporate Governance and Transparency: Compliance with US securities regulations and disclosure requirements will further enhance the company's governance standards and operational transparency, strengthening the company's compliance image and investor trust globally.

• Providing Flexibility for Future Strategic Advancement: The dual listing structure provides a richer capital operation platform and strategic options for the company's potential future international cooperation, mergers and acquisitions, and business expansion.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10